Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Michael Perch
University of Copenhagen Copenhagen, Denmark
Dr Michael Perch is the director of the national Danish lung transplant programme at Rigshospitalet and associate professor of Clinical Medicine in the Department of Clinical Medicine at the University of Copenhagen in Denmark.read more
Dr Perch has been on the board of the National Danish Transplant Society for 12 years, including 4 years as chairman. He also serves on the Scientific Advisory Committee for the Centre for Personalised Medicine of Infectious Complications in Immune Deficiency (PERSIMUNE) and the board for the Management of Post-Transplant Infections in Collaborating Hospitals (MATCH). He is currently on the Scandia transplant board and is also the associate medical director of the International Thoracic Transplant Registry, the chair of the European Respiratory Society Transplantation Group 8.02, and the treasurer of the European Society of Heart and Lung Transplantation.
Dr Perch actively contributes to numerous academic clinical trials. His expertise extends to primary graft dysfunction, chronic lung allograft dysfunction, infections and immunosuppression. Additionally, he plays a key role in the development and study of treatments within interventional pulmonology.
Dr Michael Perch discloses: Advisory board or panel fees from TFF Pharmaceuticals and Zambon. >Consultancy fees from Novo Nordisk, Ryme Medical and Takeda. Grants/research support from Pulmonx. Speaker bureau fees from AstraZeneca and Takeda.
Dr Howard J Huang
Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA
Dr Howard J Huang is the medical director of the lung transplant programme at Houston Methodist JC Walter Jr. Transplant Center and an associate professor of Clinical Medicine at Weill Cornell Medical College, Houston, TX, USA. read more
Dr Huang completed an internal medicine internship and residency at Parkland Memorial Hospital/UT Southwestern Medical Center in Dallas, and a fellowship in pulmonary and critical care medicine at Barnes Jewish Hospital/Washington University School of Medicine in St. Louis, Missouri. In 2014 Dr Huang became the associate medical director of Lung Transplantation and director of Lung Transplant Research. He has received funding from the National Institutes of Health, the American Thoracic Society and the International Society for Heart and Lung Transplantation. Dr Huang combines his interests in clinical and translational research with helping lung transplant patients achieve better long-term outcomes.
Dr Howard Huang discloses: Advisory board or panel fees from CareDx, Lung Bioengineering and Zambon. Speaker bureau fees from Boehringer Ingelheim and Takeda.
Dr Aldo Iacono
Hofstra University/Northwell Health Hempstead, NY, USA
Dr Aldo Iacono is a professor of cardiovascular and thoracic surgery at the Zucker School of Medicine at Hofstra/Northwell Health, and the medical director of the Northwell Health Lung Transplantation Program in Hempstead, NY, USA. read more
Dr Iacono is widely recognized as an expert in lung transplantation and advanced lung diseases and he currently leads a multidisciplinary surgical and medical team in providing clinical and academic care. Dr Iacono has vast experience in the field since 1992 having developed lung transplant programmes in clinical and academic medicine, and surgery, at the University of Pittsburgh and the University of Maryland School of Medicine. He was awarded the rank of Distinguished Professor in 2017 by the University of Maryland. Dr Iacono has authored over 120 publications. Alongside his clinical work, teaching and training fellows is a priority for Dr Iacono, having mentored over 95 surgical residents and fellows, including the current surgical director of cardiothoracic transplant at Northwell Health.
Dr Aldo Iacono discloses: Other financial or material support (royalties, patent, etc.): Patent for aerosol cyclosporine. Stock or shareholder (self-managed) of AI Therapeutics (relationship terminated).
